Quantcast

Industry news that matters to you.  Learn more

Metabolic Test May Predict Pregnant Women at Risk for Preeclampsia

Women can be vulnerable to sudden, sometimes dangerous spikes in blood pressure during pregnancy, part of a condition called preeclampsia. And now scientists say they’ve developed a high-tech method to predict which women are most prone to preeclampsia in late pregnancy — long before symptoms arise.

The approach relies on so-called “metabolic profiling” to track telltale metabolites found in blood plasma. The researchers say these changes could be key indicators for preeclampsia risk.

ProxiScan Completes First Animal Tests

The first animal studies made using a 2009 R&D 100 Award-winning technology were recently performed at Molecular Insight Pharmaceuticals (MIP) in Cambridge, Mass. A new small molecule drug, Trofex, was successfully tested for its effectiveness as a biomarker for the detection of prostate cancer.

$9.1 Million Grant To Improve Drug Therapy Using Gene Profiles

The National Institute of General Medical Sciences has awarded a $9.1 million, five-year grant to The Ohio State University for a study titled “Expression Genetics in Drug Therapy.” The goal of the research is to enhance drug response rates and reduce the number of adverse drug reactions among patients taking medication.

GeneNews Expected to Debut ColonSentry in New York by Year’s End

GeneNews is expected to debut in its ColonSentry colorectal cancer screening LDT in New York State either by the end of the year or within the first three months of 2011, according to an equities analyst.

Reni Benjamin of Rodman & Renshaw on Tuesday said GeneNews’s R&D partner Enzo Biochem’s clinical lab division has finished validating the PCR-based test, and is about to submit the final data package to state regulators.

Clarient Receives Patents for Taxane Biomarker

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that the United Kingdom Patent Office has granted a U.K. patent on the Company’s TLE3 biomarker, a marker which may be used to predict which cancer patients will respond favorably to taxane therapy. In addition, the Company has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a U.S. patent on the TLE3 biomarker. Other patents for the TLE3 biomarker are pending in the U.S., Canada, Japan, China, India and elsewhere in Europe.